Daré Bioscience (DARE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao from H.C. Wainwright maintained a Buy rating on the stock and has a $12.00 price target.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Douglas Tsao has given his Buy rating due to a combination of factors, primarily focusing on Daré Bioscience’s strategic initiatives and partnerships. The company has taken significant steps towards commercializing its sildenafil cream by partnering with Rosy Wellness, a women’s health app with a substantial user base. This partnership is expected to enhance product awareness and engagement among potential users, particularly those concerned with arousal issues.
Furthermore, Daré’s strategy to utilize 503B-registered outsourcing for early market entry is seen as a smart move, allowing them to introduce their product without waiting for lengthy FDA approval processes. This approach not only accelerates market presence but also increases patient awareness. Additionally, Daré’s plans to launch other women’s health solutions, including hormone therapy and vaginal probiotics, further strengthen its market position and potential revenue streams, justifying the Buy rating.
According to TipRanks, Tsao is a 4-star analyst with an average return of 8.9% and a 39.76% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Arcutis Biotherapeutics, and Coherus Biosciences.